The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Subscribe To Our Newsletter & Stay Updated
